Cancer Immunotherapy
Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (Azer-cel; PBCAR0191) Associated with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
Jacobson, C.A., American Society of Hematology (ASH) 2022 Annual Meeting
Development of a Clinical-Grade Meganuclease for Allogeneic CAR T Cell Production
Lape, J. et al. American Society of Gene and Cell Therapy (ASGCT) 2018 Annual Meeting.
Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine
Pires, M. et al. Journal for ImmunoTherapy of Cancer. 9,6 (2021). Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting.
Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic, Off-the-Shelf CD19-Targeting CAR-T Product, in Relapsed/Refractory (r/r) CD19+ NHL
Shah, B.D. et al. American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR T Cell Therapy
Jacobson C.A. et al. American Society of Hematology (ASH) 2019 Annual Meeting.